Drugs / BB-1705
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05217693 | Jun 2022 → Jun 2025 overdue | cancer | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB-1705 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05217693 ↗ |
| Modality | Monoclonal antibody | “engineered humanized IgG1κ monoclonal antibody” NCT05217693 ↗ |
| Route | Intravenous | “BB-1705 will be administered as an intravenous infusion” NCT05217693 ↗ |